Transcatheter Embolization and Occlusion Devices | China | 2017 | Market Analysis
The Chinese market for TEO devices is a growing, dynamic, and complex market driven by continual device improvement and adoption of new, innovative products from both global and domestic Chinese companies.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for TEO devices in China across a 10-year period.
INR flow-diverting devices will become available in China for the first time in 2017 and will be rapidly adopted.
How will these devices impact procedure volumes for other INR TEO devices?
Which competitor will be first to market, and what strategy will each of the competitors adopt in this space?
The embolization particle segment remains one of the most attractive markets in China due to its strong revenue potential.
Which types of embolization particles have been adopted most rapidly in China?
How will the high incidence of HCC in China affect the embolization particle market over the forecast period?
When will radioembolization spheres become available, and what impact will they have on other types of embolization particles?
Mergers and acquisitions have been a defining characteristic of the TEO device competitive landscape in recent years.
How have manufacturers gained a competitive advantage through technology acquisition?
Which market segments are the most dynamic in terms of mergers and acquisitions?
What M&A strategies should foreign and domestic companies adopt, respectively?
